GeneDx said Q2 revenue rose 49% to $102.7M, raised full-year guidance, and described expanding coverage, NICU growth, and Fabric Genomics integration.
A milestone quarter has pushed GeneDx’s momentum into the spotlight, with revenue crossing $100 million for the first time in its history.
In its Q2 2025 earnings discussion, the company highlighted that total revenue reached $102.7 million, a 49% year-over-year increase, while exome and genome revenue grew faster, reaching $85.9 million.. GeneDx also tied results to higher reimbursement rates, and it said average reimbursement per exome and genome test was over $3,700.
The focus keyphrase in the center of the quarter was WGS-driven growth dynamics, with the company reporting 23,102 exome and genome tests in the period, up 28% from the prior-year quarter.. Management also said the mix shifted toward exome and genome in a way that supported record adjusted gross margin of 71%.
After the numbers landed, GeneDx pointed to the business engine behind the quarter: improved reimbursement and tighter revenue cycle execution.. It also described adjusted operating expenses of $58 million, while emphasizing that operating expenses declined as a share of revenue versus the year-ago comparison.
One of the most immediate takeaways was profitability. The company reported $15 million in adjusted net income, marking the fourth consecutive quarter of adjusted profitability, and it ended the quarter with $135.5 million in cash, cash equivalents, and marketable securities.
Insight: This kind of quarter-to-quarter margin and reimbursement improvement matters because it changes how sustainable growth can look to investors, particularly in markets where payer behavior can swing the timeline of collections.
Looking ahead, GeneDx raised its full-year revenue guidance to a range of $400 million to $415 million.. It also reaffirmed expectations for exome and genome volume growth of at least 30% and increased its adjusted gross margin outlook to 68%-71%, while reiterating its commitment to adjusted net profitability each quarter for the rest of the year.
The company’s narrative also leaned heavily on expansion beyond its core base of pediatric neurologists.. Management described new market activity including pediatric immunology and additional indications such as cerebral palsy, along with preparations for broader pediatrician adoption tied to educational and access initiatives.
Meanwhile, GeneDx said its Fabric Genomics integration is progressing according to plan, with Fabric expected to broaden data capabilities and support automation and interpretation through proprietary AI algorithms.. It also discussed Epic Aura implementation, stating that multiple health systems are live and that more are expected later in the year.
Insight: For patients and clinicians, the operational goal behind these updates is straightforward: faster, more accessible genomic testing pathways that fit into real clinical workflows, rather than staying limited to specialized settings.
In the question-and-answer portion, management addressed the practical mechanics behind reimbursement, describing a continued focus on reducing denials and avoiding unnecessary documentation hurdles.. It also commented on the timeline for general pediatricians, saying near-term contribution this year is expected to be minimal while volumes are targeted to build more meaningfully in 2026 and beyond.
At the end of the call, GeneDx returned to its broader framing of proactive genomic care and expanding access to genomic insights.. The company said it expects to continue building execution, innovation, and payer coverage momentum as it works through multiple growth catalysts, including NICU expansion and product enhancements for non-specialist ordering.